**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 31023**

**Manuscript Type: CASE REPORT**

**Supraclavicular lymph node metastases from malignant gastrointestinal stromal tumor of the jejunum: A case report with review of the literature**

Ma C *et al.* Supraclavicular LN metastases from GIST

Chi Ma, Shao-Long Hao, Xin-Cheng Liu, Jin-Yao Nin, Guo-Chang Wu, Li-Xin Jiang, Alessandro Fancellu, Alberto Porcu, Hai-Tao Zheng

**Chi Ma, Jin-Yao Nin, Guo-Chang Wu, Li-Xin Jiang, Hai-Tao Zheng**, Department of Gastrointestinal and Thyroid Surgery, Yuhuangding Hospital Affiliated to Qingdao University, Yantai 264000, Shandong Province, China

**Shao-Long Hao, Xin-Cheng Liu**, Qingdao University Medical College, Qingdao 266021, Shandong Province, China

**Alessandro Fancellu, Alberto Porcu**, Unit of General Surgery, Department of Clinical and Experimental Medicine, University of Sassari, 07100 Sassari, Italy

**Author contributions:** Ma C drafting of the manuscript, acquisition of material; Hao SL and Liu XC collected of material; Ning JY collected of patient’s information; Wu GC revised of the manuscript, collected of patient’s information; Jiang LX revised of the manuscript; Fancellu A and Porcu A revised of the manuscript and modification of language; Zheng HT drafting of the manuscript, acquisition of patient’s information.

**Institutional review board statement:** Approved by the Yuhuangding Hospital Affiliated to Qingdao University Institutional Review Board.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There is no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Hai-Tao Zheng,** **PhD,** Department of Gastrointestinal and Thyroid Surgery, Yuhuangding Hospital Affiliated to Qingdao University, No. 20 Yuhuangdingdong Road, Zhifu District, Yantai 264000, Shandong Province, China. [machi\_sdu@163.com](mailto:machi_sdu@163.com)

**Telephone:** +86- 535-6691999

**Received:** October 26, 2016

**Peer-review started:** October 28, 2016

**First decision:** December 19, 2017

**Revised:** January 5, 2017

**Accepted:** January 18, 2017

**Article in press:**

**Published online:**

**Abstract**

Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal tumors of the alimentary tract. These tumors may have different clinical and biological behavior. Malignant forms usually spread *via* hematogenous route, and lymph nodes metastases rarely occur. Herein, we report a case history of a patient with jejunal GIST who developed supraclavicular lymph nodes metastasis. This observation suggests that lymphatic diffusion viamediastinal lymphatic station to the supraclavicular lymph nodes can be a potential metastatic way of GISTs.

**Key words:** Gastrointestinal stromal tumor; Metastasis; Lymph nodes

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** As we know, unlike gastrointestinal carcinomas, lymph node metastases rarely develop in patients with malignant gastrointestinal stromal tumors (GISTs). We report a case with history of jejunal GIST who developed supraclavicular lymph nodes metastasis and review the related literatures. This observation suggests that lymphatic diffusion *via* mediastinal lymphatic station to the supraclavicular lymph nodes can be a potential metastatic way of GISTs.

Ma C, Hao SL, Liu XC, Nin JY, Wu GC, Jiang LX, Fancellu A, Porcu A, Zheng HT. Supraclavicular lymph node metastases from malignant gastrointestinal stromal tumor of the jejunum: A case report with review of the literature. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal tumors of the alimentary tract. These tumors may have different clinical and biological behavior. Malignant forms usually spread *via* hematogenous route, and lymph nodes metastases rarely occur. Herein, we report a case history of a patient with jejunal GIST who developed supraclavicular lymph nodes metastasis.

**C****ASE REPORT**

A 56-year-old man with a 24-hour history of melena was admitted to the gastrointestinal department of the Yuhuangding Hospital affiliated with Qingdao University, China. Laboratory assessment revealed a hemoglobin level of 8 g/dL. Urgent gastroduodenoscopy, colonoscopy, and enhanced computed tomography (CT) did not reveal any source of bleeding. During the next 24 h, the patient had further episodes of melena and became hemodynamically unstable despite receiving a transfusion of 5 units of packed red blood cells and hemostatic agents. Therefore, emergency laparotomy was performed. Upon surgical exploration, a bleeding solid mass was found in the jejunum. Then, resection of a small bowel loop measuring 20 centimeters in length was performed. Upon gross examination, a nodular well-encapsulated tumor, measuring 2 cm, was found. Upon microscopic examination, histologic sections showed a GIST infiltrating through all bowel layers, and it had features of mixed spindle and epithelioid types of cells. The mitotic index was > 5/50 high-power ﬁelds (HPFs). There was no infiltration of the surgical margins, and two harvested lymph nodes were free of metastases (Figure 1). Immunohistochemical studies showed positivity for CD117, CD34, and Dog-1; the Ki67 index was 20%. Therefore, the diagnosis was GIST of the small intestine with high-grade malignancy based on the modified NIH GIST criteria[[1](#_ENREF_1)]. Postoperative total body CT scan and positron emission tomography-computed tomography (PET-CT) were negative for metastatic disease. The patient was offered adjuvant imatinib therapy, but he declined due tofamily and economic reasons.

One year later, the patient was admitted to the thyroid department at same hospitalcomplaining of a left cervical massthat had been gradually enlarging over one month. Ultrasound revealed a hypoechoicmass above the left clavicle, measuring 3.1 cm × 4.6 cm; this mass was unenhanced in a contrast-enhanced CT scan (Figure 2 and 3). Interestingly, there were noalterations of the thyroid in imaging studies. Core needle biopsy was performed, and histopathological examination with hematoxylin-eosin stainingrevealed lymph node metastasis from a GIST. Immunohistochemistry studies demonstrated positivity for CD117, CD34, and vim, whereas calponin, estrogen, progesterone, and thyroglobulin were negative. A PET-CT scan showed uneven FDG uptake in the cervical mass and multiple lymph nodes in the mediastinum (Figure 4). The patient underwent surgical removal of the cervical mass. Gross examination of the excised lymph node demonstrated that it measured 5 cm × 6 cm × 8 cm and appeared irregular, smooth, and well encapsulated. Histopathologic examination again confirmed a metastasis from a GIST (Figure 5). Immunohistochemical studies of the resected lymph node showed positivity for CD117 and CD34and negativity for Dog-1 and S-100. The Ki67 index was 30%. Insertion of GCC TAT in exon 9 of the c-KIT gene was identified with mutation analysis. Exons 11, 13, and 17 and the PDGFRα gene were wild type. After the second operation, the patient was regularly given imatinib at a dose of 400 mg per day. At 1 year following the surgery, the patient was asymptomatic, and there wereno signs of tumor recurrence or progression (Table 1).

**DISCUSSION**

GISTs represent the most common neoplasms of mesenchymal origin of the gastrointestinal tract. GISTs may have different clinical and biological behavior, ranging from small benign tumors to aggressive forms that have a dismal prognosis. Approximately 20%-25% of GISTs are located in the stomach, and 40%-50% of those located in the small intestine can be considered as malignant neoplasms with features such as local recurrence after surgical removal, intraperitoneal dissemination and distant metastases[[2](#_ENREF_2)]. However, unlike gastrointestinal carcinomas, lymph node metastases (LNMs) rarely develop in patients with malignant GISTs. In fact, the mainstay of treatment for GISTs is complete surgical resection without a regional lymphadenectomy[[3](#_ENREF_3),[4](#_ENREF_4)].

In the literature, the rates of lymph node metastases from GISTs range from 0 to 5%[[3](#_ENREF_3),[5](#_ENREF_5),[6](#_ENREF_6)]. The few studies reporting on this subject are summarized in Table 1[[5](#_ENREF_5),[7-19](#_ENREF_7)]. Most of the reported cases are peritumoral lymph nodes metastases, which have occasionally been discovered with histopathological examination of surgical specimens. We found only 3 cases that could be defined as distant LNMs[[14](#_ENREF_14),[18](#_ENREF_18)]，including 2 inguinal lymph nodes and 1 axillary lymph node. In the case described herein, LNMs developed in left supraclavicular and mediastinal basins. This behavior is similar to that observed in malignant gastrointestinal tumors that have an epithelial origin. To the best of our knowledge, this is the first caseof the lymphatic spread of a gastric GISTto supraclavicular and mediastinum lymph nodes. This might indicate that a particular subgroup of GISTs has biological characteristics similar to carcinomas.

According to the modified NIH GIST criteria, the case was a high-grade GIST malignancy[[1](#_ENREF_1)]. Ki67 expression changed from 20% in the primary tumor to 30% in the supraclavicular metastasis. Interestingly, Dog-1 was negative in the LNM, whereas it was positive in primary tumor. It could be speculated that the Ki67 and Dog-1 levels may be markers of the primary tumor de-differentiation tendency.

Activating mutations of the c-kit gene (especially exons 11 and 9) are present in most GISTs and probably play a fundamental role in the development of these tumors. Among the reported cases of LNMs from GISTs, few gene detection results have been described, most of which are exon 11 mutations[[5](#_ENREF_5),[7](#_ENREF_7),[13](#_ENREF_13),[14](#_ENREF_14)]. In the study by Kong *et al*[[13](#_ENREF_13)], the exon 11 mutation was linked to the likelihood of LNMs. However, in the case described herein, we found an exon 9 mutation. This genetic mutation in the LNMs from GISTs has not been reported to date. The relationship between gene mutations and LNMs is still not clear, but many authors have stated that KIT exon 9-mutant tumors demonstrates imatinib resistance more frequently than exon 11-mutant tumors[[20](#_ENREF_20),[21](#_ENREF_21)]. Cases with exon 9-mutant tumors should be treated with increased imatinib doses. Because the patient declined imatinib treatment after the first surgery, he was treated with 400 mg of imatinib per day after the second operation.

In conclusion, complete surgical resection remains the mainstay of treatment for resectable GISTs. Imatinib is currently indicated for the first-line treatment of patients with metastatic or unresectable KIT-positive GISTs. Adjuvant therapy with imatinib was deemed necessary for this patient following complete resection of a primary jejunual tumor because it was an aggressive, high-risk form of GIST. Unfortunately, he did not take imatinib after his first operation, and distant lymph node metastases occurred after 12 months. Following the second operation, the patient received imatinib treatment and had survived without disease progression atthe 1-yearfollow up.

This case confirms that LNMs in the mediastinum and supraclavicular lymph nodes is a potential metastatic route for malignant GISTs. Further studies are needed to clarify the mechanism of lymph node metastases in patients with GISTs.

**COMMENTS**

***Case characteristics***

The patient was admitted to hospital with complaining of a left cervical mass, which had been diagnosed as jejunum gastrointestinal stromal tumors (GISTs) and cured by operation 1 year before.

***Clinical diagnosis***

To identify the differential diagnoses of thyroid tumor, lymphoma, metastatic carcinoma, the patient was carried on computed tomography (CT), ultrasound (US), positron emission tomography-computed tomography (PET-CT) and biopsy. US, CT and PET-CT revealed a hypoechoic, unenhanced and uneven FDG uptake mass above the left clavicle measuring 3.1 cm × 4.6 cm.

***Laboratory diagnosis***

After a biopsy of the cervical mass, this patient was diagnosed as supraclavicular lymph node metastases from GISTs.

***Pathological diagnosis***

Core needle biopsy was carried out, and the histopathological examination on hematoxylin-eosin stain showed lymph node metastasis from GIST.

***Treatment***

The patient underwent surgical removal of the cervical mass and was regularly given imatinib 400 mg per day

***Experiences and lessons***

This case confirms that LNM in the mediastinum and supraclavicular lymph nodes are a potential metastatic way of malignant GISTs, so they should attach importance to this during operation and chemotherapy. Due to the first case repot, we try to give some but not sufficient evidence of the possible mechanisms of spread of the supraclavicular lymph node metastasis.

***Peer-review***

This case report is well organized and had much information including genetic analysis data on primary GIST and metastatic lesion.

**REFERENCES**

1 **Joensuu H**. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. *Hum Pathol* 2008; **39**: 1411-1419 [PMID: 18774375 DOI: 10.1016/j.humpath.2008.06.025]

2 **Miettinen M**, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. *Arch Pathol Lab Med* 2006; **130**: 1466-1478 [PMID: 17090188 DOI: 10.1043/1543-2165(2006)130]

3 **DeMatteo RP**, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000; **231**: 51-58 [PMID: 10636102]

4 **Pierie JP**, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. *Arch Surg* 2001; **136**: 383-389 [PMID: 11296107]

5 **Tashiro T**, Hasegawa T, Omatsu M, Sekine S, Shimoda T, Katai H. Gastrointestinal stromal tumour of the stomach showing lymph node metastases. *Histopathology* 2005; **47**: 438-439 [PMID: 16178904 DOI: 10.1111/j.1365-2559.2005.02133.x]

6 **Aparicio T**, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, Bonvalot S. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. *Eur J Surg Oncol* 2004; **30**: 1098-1103 [PMID: 15522557 DOI: 10.1016/j.ejso.2004.06.016]

7 **Sato T**, Kanda T, Nishikura K, Hirota S, Hashimoto K, Nahagawa S, Ohashi M, Hatakeyama K. Two cases of gastrointestinal stromal tumor of the stomach with lymph node metastasis. *Hepatogastroenterology* 2007; **54**: 1057-1060 [PMID: 17629038]

8 **El Demellawy D**, Shokry P, Ing A, Khalifa M. Polypoid gastrointestinal stromal tumor of small bowel metastasizing to mesenteric lymph nodes: a case report. *Pathol Res Pract* 2008; **204**: 197-201 [PMID: 18096326 DOI: 10.1016/j.prp.2007.10.007]

9 **Hu X**, Forster J, Damjanov I. Primary malignant gastrointestinal stromal tumor of the liver. *Arch Pathol Lab Med* 2003; **127**: 1606-1608 [PMID: 14632569 DOI: 10.1043/1543-2165(2003)127<1606: pmgsto>2.0.co; 2]

10 **Sakurai N**, Yamauchi J, Shibuma H, Ikeda E, Sasou S. [A case of recurrent GIST of the esophagus which completely responded to imatinib mesilate]. *Gan To Kagaku Ryoho* 2007; **34**: 237-240 [PMID: 17301535]

11 **Asakage N**, Kobayashi S, Gotou T, Sasaki M, Tsukada K, Suzuki T, Yamamoto T, Sekine M, Miyazaki E, Hirai S, Yamasaki S. [Two cases of gastrointestinal stromal tumor (GIST) of the stomach and a consideration of its malignancy potential and treatment strategy - report of two cases]. *Gan To Kagaku Ryoho* 2007; **34**: 919-923 [PMID: 17565257]

12 **Canda AE**, Ozsoy Y, Nalbant OA, Sagol O. Gastrointestinal stromal tumor of the stomach with lymph node metastasis. *World J Surg Oncol* 2008; **6**: 97 [PMID: 18775061 DOI: 10.1186/1477-7819-6-97]

13 **Kong M**, Wang YL, Xu LJ, Teng XD. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures]. *Zhonghua Bing Li Xue Za Zhi* 2009; **38**: 617-620 [PMID: 20079191]

14 **Zhang Q**, Yu JW, Yang WL, Liu XS, Yu JR. Gastrointestinal stromal tumor of stomach with inguinal lymph nodes metastasis: a case report. *World J Gastroenterol* 2010; **16**: 1808-1810 [PMID: 20380018]

15 **Yamada E**, Oyaizu T, Miyashita T. [A case of gastrointestinal stromal tumor of the stomach with lymph node metastasis followed up for 7 years without evidence of recurrence after surgery]. *Nihon Shokakibyo Gakkai Zasshi* 2010; **107**: 743-749 [PMID: 20460848]

16 **Masuda T**, Toh Y, Kabashima A, Aoki Y, Harimoto N, Ito S, Taomoto J, Ikeda O, Ohga T, Adachi E, Sakaguchi Y, Hirahashi M, Nishiyama K, Okamura T. Overt lymph node metastases from a gastrointestinal stromal tumor of the esophagus. *J Thorac Cardiovasc Surg* 2007; **134**: 810-811 [PMID: 17723845 DOI: 10.1016/j.jtcvs.2007.06.002]

17 **Shafizad A**, Mohammadianpanah M, Nasrolahi H, Mokhtari M, Mousavi SA. Lymph Node Metastasis in Gastrointestinal Stromal Tumor (GIST): to Report a Case. *Iran J Cancer Prev* 2014; **7**: 171-174 [PMID: 25250169]

18 **Vassos N**, Agaimy A, Hohenberger W, Croner RS. Extraabdominal lymph node metastasis in gastrointestinal stromal tumors (GIST). *J Gastrointest Surg* 2011; **15**: 1232-1236 [PMID: 21336495 DOI: 10.1007/s11605-011-1464-3]

19 **Catani M**, De Milito R, Simi M. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. *Chir Ital* 2005; **57**: 127-133 [PMID: 15832750]

20 **Heinrich MC**, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol* 2008; **26**: 5360-5367 [PMID: 18955451 DOI: 10.1200/jco.2008.17.4284]

21 **Lee JH**, Kim Y, Choi JW, Kim YS. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. *J Gastrointestin Liver Dis* 2013; **22**: 413-418 [PMID: 24369323]

**P-Reviewer:** Alimehmeti RH, Kim ST **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C


Grade D (Fair): 0

Grade E (Poor): 0


**Table 1 Clinical characteristics of cases reported**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Primary site** | **HPF** | **T size (cm)** | **Treatment** | **LNM site** | **LNM time** | **Gene mutation** |
| Sato T | gastric |  | 4 | Proximal gastrectomy | right cardia | Pre | deletion mutation in exon 11 |
| Sato T | gastric |  | 2.5 | Wedge resection +partial hepatectomy | adjacent to the tumor | Pre | No mutation |
| El Demellawy D | small bowel |  |  |  | mesenteric | Pre |  |
| Hu X | Hepatic | 4/10 | 15 × 10 | Right hepatic lobectomy | hilar | Post |  |
| Canda AE | gastric | 25/50 | 8 × 8 × 4 | distal gastrectomy +perigastric LN dissection | perigastirc | Pre | No mutation |
| Kong M | Small intestinal | 2/50 | 6 × 7 | Partial resection of the ileum | periintestine | Pre | deletion 559-569 in exon 11 |
| Kong M | Small intestinal | 2/50 | 5 × 5 | Partial resection of the ileum | periintestine | Pre | Deletion 559-565 in exon 11 |
| Qin Zhang | Gastric |  |  | distal gastrectomy, perigastriclymphadenectomy and hepatectomy | Inguinal LN | Post | deletion 557/558 in exon 11 |
| Yamada E | Gastric | > 5 / 50 | 4.5 × 3.5 | Gastrectomy+lymph node dissection | perigastirc | Pre |  |
| Catani M | Gastric |  |  | Gastrectomy+ resection of the tail of the pancreas, the spleen, and the transverse colo | perigastirc | Pre |  |
| Masuda T | Esophagus | 15/50 | 9.5 | subtotal esophagectomy | Periesophagus | Pre |  |
| Amin Shafizad | Gastric |  | 8 | total gastrectomy and omentectomy | perigastirc | Pre |  |
| Vassos N | Ileum |  |  | Partial resection of the ileum | Inguinal | Pre |  |
| Vassos N | Gastric |  |  | extended gastrectomy, atypical liver resection, splenectomy | Axillary | Post |  |
| Sakurai N | Esophagus |  |  | Middle and lower esophagectomy | multiple | Post |  |
| Asakage N | Gastric |  |  | total gastrectomy with distal pancreatosplenectomy and segmental liver resection | perigastirc | Pre |  |
| T Tashiro | Gastric |  | 1-5 |  |  |  | No mutation |
| T Tashiro | Gastric | Ki67 10% | 2.5 | proximal gastrectomy with sampling of the regional LNs |  |  | Exon 11 |


HPF: High-power ﬁelds; LNM: Lymph node metastases.





**Figure 1 Histopathologic section of the primary tumour.** The tumor was composed of spindle and epithelioid cells, which were predominantly arranged in spiral and lace-like shape (H&E stain: × 400).




**Figure 2 Ultrasonography of cervical mass: The mass was hypoechoic, with a smooth border and un-even internal echo.**



**Figure 3 Computed tomography: The mass appeared as a low density cyst with clear edge without contrast enhancement.**

**Figure 4 Positron emission tomography-computed tomography: FDG accumulated unevenly in the cervical mass and multiple lymph nodes in mediastinum.**



**Figure 5 Histopathologic section of the cervical tumour (HE staining).** The epithelioid cells were sheet arranged, with abundant eosinophilic cytoplasm and prominent nuclei (HE staining × 400).